within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01A_AnteriorPituitaryLobeHormonesAndAnalogues.H01AC05_MecaserminRinfabate;

model MecaserminRinfabate
  extends Pharmacolibrary.Drugs.ATC.H.H01AC05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>H01AC05</td></tr><td>route:</td><td></td></tr><tr><td>n-compartments</td><td>0</td></tr></table><p>Mecasermin rinfabate is a combination of recombinant human insulin-like growth factor 1 (rhIGF-1, mecasermin) and recombinant human insulin-like growth factor binding protein 3 (rhIGFBP-3). It was developed for the treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. The drug is not currently approved and is not on the market.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data specific for mecasermin rinfabate in humans is available. Estimates below are generic or based on related IGF-1 compounds. Parameters left blank where no direct data is available.</p><h4>References</h4><ol><li><p>Kemp, SF (2007). Mecasermin rinfabate. <i>Drugs of today (Barcelona, Spain : 1998)</i> 43(3) 149–155. DOI:<a href=&quot;https://doi.org/10.1358/dot.2007.43.3.1079876&quot;>10.1358/dot.2007.43.3.1079876</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17380212/&quot;>https://pubmed.ncbi.nlm.nih.gov/17380212</a></p></li><li><p>Williams, RM, et al., &amp; Dunger, DB (2008). Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX. <i>Expert opinion on drug metabolism &amp; toxicology</i> 4(3) 311–324. DOI:<a href=&quot;https://doi.org/10.1517/17425255.4.3.311&quot;>10.1517/17425255.4.3.311</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18363546/&quot;>https://pubmed.ncbi.nlm.nih.gov/18363546</a></p></li><li><p> (2005). Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. <i>Drugs in R&amp;D</i> 6(2) 120–127. DOI:<a href=&quot;https://doi.org/10.2165/00126839-200506020-00008&quot;>10.2165/00126839-200506020-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15777106/&quot;>https://pubmed.ncbi.nlm.nih.gov/15777106</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MecaserminRinfabate;
